Figure S4 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Abstract
RAS(Q61R/K) cells are insensitive to combined SHP2i+MEKi treatment due to feedback activation of RAS(Q61R/K) and induction of a SHP2 conformation with reduced binding to SHP2i
Fields of Study & Subjects
Protein Tyrosine Phosphatases
Melanoma and MAPK Pathways
Protein Kinase Regulation and GTPase Signaling
Publication details
- Publication date
- 2 January 2026